Print
Email
Print Edition StoriesThursday, July 8, 2010
Genzyme slaps Anika with IP lawsuit
By Boston Business Journal staff
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Cambridge-based Genzyme Corp. has filed a suit in U.S. District Court against Anika Therapeutics Inc., claiming its osteoarthritis treatment Monovisc infringes two Genzyme patents.
Bedford-based Anika (Nasdaq: ANIK) already sells Monovisc in Canada, Europe and Turkey and is looking for approval from the U.S. Food and Drug Administration to sell the gel-form treatment in the United States.
In its lawsuit, Genzyme (Nasdaq: GENZ) claims the injectible gel infringes on two patents, one the Cambridge company obtained in 1992 and the other obtained three years later. Genzyme is asking the court to bar Anika from selling Monovisc. Genzyme manufactures Synvisc, a gel-like mixture used to alleviate knee pain due to osteoarthritis.
“As a result of Anika’s infringement ... Genzyme has suffered and will continue to suffer irreparable harm, for which Genyzme has no adequate remedy at law,” Genzyme states in the lawsuit, which was filed July 7.
Anika reported income of $3.69 million on sales of $40 million last year.
Genzyme, one of the world’s largest makers of drugs for rare genetic diseases, reported $422.3 million in income on $4.5 billion in sales.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
